Department of Medicine, Section of Dermatology and Venereology, University of Verona, Piazzale A. Stefani 1, I-37126 Verona, Italy.
Br J Dermatol. 2013 Apr;168(4):749-55. doi: 10.1111/bjd.12118. Epub 2013 Feb 27.
Chronic plaque psoriasis is associated with obesity, which is a metabolic and inflammatory disorder. Adipokines are involved in the pathogenesis of psoriasis and they are biomarkers of obesity-related inflammation.
To measure serum adipokines in patients with chronic plaque psoriasis treated with infliximab.
Serum levels of chemerin, resistin, visfatin, C-reactive protein (CRP), lipids, glycaemia and liver enzymes were measured in 40 patients with psoriasis and 40 controls matched by age, sex and body mass index (BMI). Adipokines were measured at baseline and after 2-12 months of treatment with infliximab 5 mg kg(-1).
At baseline, levels of chemerin (195·9±48·5 vs. 145·6±27·1 ng mL(-1)), resistin (2·03±0·9 vs. 1·4±0·5 ng mL(-1)) and CRP (5·5±7·3 vs. 1·9 ±4·4 mg L(-1)) were higher (P<0·01) in patients with psoriasis compared with controls. Psoriasis was associated with elevated chemerin level independently of age, sex, BMI and levels of cholesterol and triglycerides. Chemerin was linearly correlated to CRP (r=0·4, P=0·01) and resistin (r=0·3, P=0·01). Chemerin levels were higher in patients affected by psoriatic arthritis than in patients with psoriasis without arthritis (195·5±49·1 vs. 158·1±37·5 ng mL(-1), P=0·01). After 2 months of infliximab treatment a significant reduction of chemerin, resistin and CRP levels was observed.
Patients with psoriasis have higher blood levels of adipokines, which normalize during therapy with infliximab. Whether this reduction is a direct effect of infliximab or secondary to a reduction of inflammation should be further investigated.
慢性斑块状银屑病与肥胖有关，后者是一种代谢和炎症紊乱。脂肪因子参与银屑病的发病机制，它们是肥胖相关炎症的生物标志物。
测量接受英夫利昔单抗治疗的慢性斑块状银屑病患者的血清脂肪因子水平。
测量 40 例银屑病患者和 40 例年龄、性别和体重指数（BMI）匹配的对照者的血清趋化素、抵抗素、内脂素、C 反应蛋白（CRP）、血脂、血糖和肝酶水平。在接受英夫利昔单抗 5mg/kg 治疗 2-12 个月后测量脂肪因子。
基线时，银屑病患者的趋化素（195.9±48.5 比 145.6±27.1ng/ml）、抵抗素（2.03±0.9 比 1.4±0.5ng/ml）和 CRP（5.5±7.3 比 1.9±4.4mg/L）水平较高（P<0.01）。银屑病与独立于年龄、性别、BMI 以及胆固醇和甘油三酯水平的趋化素水平升高有关。趋化素与 CRP（r=0.4，P=0.01）和抵抗素（r=0.3，P=0.01）呈线性相关。伴有银屑病关节炎的患者的趋化素水平高于无关节炎的银屑病患者（195.5±49.1 比 158.1±37.5ng/ml，P=0.01）。接受英夫利昔单抗治疗 2 个月后，趋化素、抵抗素和 CRP 水平显著降低。
银屑病患者的血液脂肪因子水平较高，接受英夫利昔单抗治疗后可恢复正常。这种降低是英夫利昔单抗的直接作用还是炎症减轻的继发作用，还需要进一步研究。
